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To the Editor:
We read with interest the article 
by Powell et al.1 on the risk of lung 
cancer (LC) in patients with chronic 
obstructive pulmonary disease (COPD). 
The authors literally concluded that 
“… a diagnosis of COPD is strongly 
associated with a diagnosis of LC, 
however, this association is largely 
explained by smoking habit, strongly 
dependent on the timing of COPD 
diagnosis, and not specific to COPD. It 
seems unlikely, therefore, that COPD 
is an independent risk factor for lung 
cancer.”1 We congratulate the authors 
for their study but respectfully dis-
agree regarding their interpretation of 
results and conclusions for the reasons 
explained below.
Using a U.K. general prac-
tice database (Health Improvement 
Network), Powell et al.1 identified 
11,888 incident cases of LC, 23% 
of whom had a prior diagnosis of 
COPD compared with only 6% of 
37,605 controls matched for age, sex, 
and practice. The odds ratio (OR) of 
LC in patients who had COPD diag-
nosed within 6 months of their can-
cer diagnosis were 11-fold those of 
patients without COPD (11.47, 95% 
confidence interval [CI]: 9.38–14.02). 
When, for reasons unclear to us, anal-
ysis was restricted to those cases with 
COPD diagnosed more than 10 years 
before LC diagnosis with, impor-
tantly, adjustment for smoking, the 
OR decreased to 2.18 (95% CI: 1.87–
2.54). Given that the OR is the ratio 
of the odds of an event occurring in 
one group to the odds of it occurring 
in another group, we think that these 
remarkable results should be inter-
preted differently because they: (1) 
confirm that smoking is a major risk 
factor for both COPD and LC (OR: 
11.47) and (2) demonstrate that, after 
adjusting for smoking and time since 
COPD diagnosis, the risk of develop-
ing LC is 2.18 times higher in smokers 
with COPD and that this is statistically 
significant (95% CI: 1.87–2.54). In 
other words, those smokers who are 
susceptible to the effects of smoking 
and develop COPD (not all smokers) 
have more than twice the risk of devel-
oping LC than smokers who manage 
to preserve their lung function within 
the normal range despite their habit. 
To put it simply, these results clearly 
show that COPD is an independent 
risk factor for LC. This interpretation 
is opposite to that offered by Powell et 
al.1 but potentially very important in 
any program of LC screening2 in which 
cost–benefit ratio is proportional to 
the specific population screened.3
REFERENCES
 1. Powell HA, Iyen-Omofoman B, Baldwin DR, 
Hubbard RB, Tata LJ. Chronic obstructive 
pulmonary disease and risk of lung cancer: 
the importance of smoking and timing of 
diagnosis. J Thorac Oncol 2013;8:6–11.
 2. The National Lung Screening Trial Research 
Team. Reduced lung-cancer mortality with 
low-dose computed tomographic screening. 
New Eng J Med 2011;365:395–409.
 3. Sekine Y, Katsura H, Koh E, Hiroshima K, 
Fujisawa T. Early detection of COPD is 
important for lung cancer surveillance. Eur 
Respir J 2012;39:1230–1240.Disclosure: The 
authors declare no conflict of interest.
To the Editor:
We thank Drs. Molins and Agusti 
for their interest in our article1 and for 
their comments. We agree entirely that 
our results are of great importance in 
the lung cancer screening setting. In 
our view, however, this is because of 
the strength of the unadjusted asso-
ciation between chronic obstruc-
tive pulmonary disease (COPD) and 
lung cancer, and the fact that COPD 
is essentially an excellent marker for 
smoking. Diagnoses of COPD could 
potentially identify patients who do 
not admit to either their smoking habit 
or the quantity.
The idea that smokers who 
develop COPD are the ones who are 
susceptible to lung cancer, and those 
who smoke but do not develop COPD 
are less likely to develop lung cancer, 
is not unreasonable. In our opinion, 
however, the evidence for an indepen-
dent association is weak as it relies on 
adjustment for a confounder, which in 
itself increases the risk of lung cancer 
more than 15-fold, and which is mea-
sured almost exclusively by patient 
reported quantity smoked. Since at 
least the 1950s, we have known that 
cigarette smoking is harmful, and 
smoking cessation is widely promoted 
during medical consultations. It is 
highly likely that smoking quantity 
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would be necessary in 26 of the 141 
patients studied. All but one of these 
patients belonged to the cohort that devel-
oped radiation pneumonitis. The mean 
clinically prescribed dose to this pneumo-
nitis population was 64.7 Gy as opposed to 
51.8 Gy predicted to be safe by the model. 
For a subset of the remaining patients, 
the dose could be slightly increased or 
decreased. This finding is intriguing keep-
ing in mind that dose escalation in lung 
radiotherapy is thought to substantially 
increase local tumor control and ulti-
mately survival.4 Instead of decreasing 
the dose to prevent patients from develop-
ing unwanted side effects, more tailored 
solutions are feasible. van Baardwijk et 
al.5 successfully pioneered an individual-
ized approach escalating dose to maxi-
mal tolerance while keeping within the 
normal-tissue constraints, both theoreti-
cally and clinically. Both acute and late 
toxicity were acceptable. Additionally, 
MAASTRO clinic is currently conduct-
ing a randomized phase II trial including 
18F-fluorodeoxyglucose-positron emis-
sion tomography information for tumor 
(subvolume) boosting (NCT01024829). 
On the basis of a recent in silico study,3 
Radboud University Nijmegen Medical 
Centre is carrying out the Individualized 
Dose Escalation in Advanced stage non-
small cell Lung cancer using Volumetric 
Modulated Arc Therapy (IDEAL-VMAT) 
study (NCT01577212), whereby the 
irradiation dose is increased on an indi-
vidual basis, taking into account multiple 
 normal-tissue constraints.
For patients with both an unfavor-
able genetic profile and dose distribu-
tion, the radiation dose that can be safely 
administered on the basis of the proposed 
model is probably not curative. Therefore, 
the treating radiation oncologist may opt 
for a palliative protocol thereby deceler-
ating tumor progression and alleviating 
tumor-associated complaints while pre-
venting patients from unnecessary treat-
ment-related side effects.
In summary, this article on model-
based prescription provides new, yet 
prospectively unvalidated, tools for indi-
vidualized dose-prescription in non–
small-cell lung cancer patients. Radiation 
oncologists are encouraged to enhance 
radiation dose in patients with a favorable 
profile while seeking alternative thera-
peutic options in the remaining patients.
To the Editor:
With great interest, we read the 
recent publication by Vinogradskiy et 
al.1 The authors apply their radiation 
pneumonitis prediction model combin-
ing dose-volume and genetic compo-
nents (single-nucleotide polymorphisms 
[SNPs]) for isotoxic mean lung dose 
determination. The five SNPs were 
found to predict for radiation pneumoni-
tis and interestingly, they do not directly 
relate to lung injury, but rather to cellular 
repair and the tumor microenvironment.
The authors state that radiation 
pneumonitis is the dominant dose- 
limiting constraint in thoracic radiother-
apy. This may have been the case for the 
cohort studied for 19% of the patients, 
mostly treated with three-dimensional 
conformal radiotherapy developed radi-
ation pneumonitis of grade 3 or higher. 
With the introduction of highly confor-
mal radiotherapy delivery techniques 
and by abandoning elective nodal irra-
diation, acute grade 3 esophagitis is 
increasingly the dose-limiting toxicity 
based both on clinical experience2 and 
in silico studies.3 As opposed to radia-
tion pneumonitis, this burdensome side 
effect is not fatal but gradually develops 
during the course of (chemo)radiother-
apy, lasting for several weeks thereaf-
ter necessitating analgesic medication 
and dietary alterations in the majority 
of patients. Moreover, late esophageal 
sequelae may develop, adversely influ-
encing the patients’ quality of life.
Vinogradskiy et al.1 found that on 
the basis of the isotoxic physico-genetic 
model a reduction in prescribed dose 
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and duration are under-reported by 
patients and therefore impossible to 
completely exclude from any esti-
mate of the association between the 
two diseases which are both strongly 
related to smoking.
Although we accept that our 
study does not completely exclude an 
independent effect of COPD on the 
risk of lung cancer, our own opinion 
is that the remaining association can 
be explained by residual confounding 
and that any truly independent effect 
would be very small, and certainly 
lower than a twofold increase. The 
importance of our interpretation lies 
in the allocation of resources in lung 
cancer research, which we believe 
should not be focused on the pursuit of 
a potential molecular link, but rather 
on early detection, novel and improved 
treatments, and smoking cessation.
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